Artiva Biotherapeutics, INC 10-Q quarterly reports

Artiva Biotherapeutics announces positive initial clinical data for AlloNK in autoimmune diseases, with a planned Phase 3 trial in refractory RA.

Artiva Biotherapeutics reported a wider net loss in Q3 2025 as research and development expenses surged, while the company prioritizes its lead candidate AlloNK for refractory rheumatoid arthritis with a new Fast Track designation.

Artiva Biotherapeutics reported increased net losses and cash burn in Q2 2025, while strategically shifting its clinical focus to autoimmune diseases with its lead candidate AlloNK.

Artiva Biotherapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic initiatives.

Artiva Biotherapeutics reports its third quarter 2024 financial results, highlighting a shift from collaboration revenue to a focus on internal development following a successful IPO.

Artiva Biotherapeutics reports a net loss of $31.8 million for the first half of 2024, while highlighting progress in clinical trials and a successful IPO.